Exhibit 99.1

The following tables present revenues, expenses and profit for each segment for the years ended December 31, 2023 and 2022, and for the three months ended December 31, 2023, September 30, 2023, June 30, 2023 and March 31, 2023:

		United States Segment
		Year ended December 31,								Three months ended
		2023				2022				December 31,				September 30,				June 30,				March 31,
										2023
		(Unaudited, U.S.$ in millions)
Revenues		$	7,731			$	7,003			$	2,266			$	1,896			$	1,892			$	1,677
Gross profit			4,310				3,734				1,444				1,060				1,017				789
R&D expenses			604				485				144				156				156				149
S&M expenses			938				879				238				243				250				207
G&A expenses			378				440				90				93				101				95
Other income			(5	)			(3	)			(1	)			(2	)			(1	)			§
Segment profit*		$	2,394			$	1,934			$	974			$	571			$	511			$	338

		Europe Segment
		Year ended December 31,								Three months ended
		2023				2022				December 31,				September 30,				June 30,				March 31,
										2023
		(Unaudited, U.S.$ in millions)
Revenues		$	4,837			$	4,525			$	1,344			$	1,146			$	1,163			$	1,184
Gross profit			2,726				2,700				783				648				640				655
R&D expenses			220				213				52				62				53				53
S&M expenses			767				748				203				184				194				187
G&A expenses			263				246				67				66				61				70
Other income			(2	)			(3	)			§				§				(1	)			§
Segment profit*		$	1,478			$	1,496			$	461			$	338			$	334			$	345

		International Markets Segment
		Year ended December 31,								Three months ended
		2023				2022				December 31,				September 30,				June 30,				March 31,
										2023
		(Unaudited, U.S.$ in millions)
Revenues		$	2,351			$	2,352			$	601			$	591			$	578			$	581
Gross profit			1,160				1,224				299				293				283				285
R&D expenses			104				119				24				30				23				27
S&M expenses			487				467				134				116				125				113
G&A expenses			142				154				37				33				34				38
Other income			(39	)			(54	)			(4	)			(2	)			(31	)			(1	)
Segment profit*		$	465			$	538			$	109			$	117			$	132			$	108

* Segment profit is comprised of gross profit for the segment less R&D expenses, S&M expenses, G&A expenses and other income related to the segment. Segment profit does not include amortization and certain other items.

1

The following tables present revenues by major products and activities for each segment for the years ended December 31, 2023 and 2022 and for the three months ended December 31, 2023, September 30, 2023, June 30, 2023 and March 31, 2023:

		United States Segment
		Year ended December 31,								Three months ended
		2023				2022				December 31,				September 30,				June 30,				March 31,
										2023
		(Unaudited, U.S.$ in millions)
Generic products			3,138				3,155				667				839				884				747
AJOVY			211				210				57				56				52				46
AUSTEDO			1,225				963				408				339				308				170
BENDEKA and TREANDA			237				309				52				56				67				62
COPAXONE			297				359				72				98				56				71
Anda			1,577				1,471				394				367				392				424
Other			1,047				536				616				142				131				158
Total		$	7,731			$	7,003			$	2,266			$	1,896			$	1,892			$	1,677

		Europe Segment
		Year ended December 31,								Three months ended
		2023				2022				December 31,				September 30,				June 30,				March 31,
										2023
		(Unaudited, U.S.$ in millions)
Generic products			3,664				3,466				938				886				909				932
AJOVY			160				124				45				41				39				36
COPAXONE			231				268				56				55				60				59
Respiratory products			265				273				70				61				66				68
Other			516				393				234				104				89				89
Total		$	4,837			$	4,525			$	1,344			$	1,146			$	1,163			$	1,184

		International markets Segment
		Year ended December 31,								Three months ended
		2023				2022				December 31,				September 30,				June 30,				March 31,
										2023
		(Unaudited, U.S.$ in millions)
Generic products			1,932				1,980				506				470				478				477
AJOVY			63				42				19				18				14				13
COPAXONE			63				64				12				16				17				17
Other			293				266				64				87				69				74
Total		$	2,351			$	2,352			$	601			$	591			$	578			$	581

2

The following tables present revenues by major products and activities for Canada for the years ended December 31, 2023 and 2022 and for the three months ended December 31, 2023, September 30, 2023, June 30, 2023 and March 31, 2023:

		Canada
		Year ended December 31,								Three months ended
		2023				2022				December 31,				September 30,				June 30,				March 31,
										2023
		(Unaudited, U.S.$ in millions)
Generic products			337				394				86				89				84				77
AJOVY			20				7				6				6				5				3
AUSTEDO			—				—				—				—				—				—
BENDEKA and TREANDA			4				7				1				1				1				1
COPAXONE			23				28				5				5				8				5
Anda			—				—				—				—				—				—
Other			9				13				1				4				1				2
Total		$	393			$	449			$	99			$	106			$	99			$	89

3